[HTML] nih.gov

[HTML][HTML] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI insight, 2016 - ncbi.nlm.nih.gov
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …
被引用次数：700 相关文章
[PDF] semanticscholar.org

[PDF][PDF] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - pdfs.semanticscholar.org
In recent years, immune checkpoint inhibitors have demonstrated promising response rates,
and gained FDA approval for use, in patients with metastatic melanoma, non–small cell lung …
[HTML] jci.org

[HTML][HTML] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI …, 2016 - Am Soc Clin Investig
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …

The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard… - JCI …, 2016 - pure.johnshopkins.edu
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …
[PDF] researchgate.net

[PDF][PDF] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - researchgate.net
In recent years, immune checkpoint inhibitors have demonstrated promising response rates,
and gained FDA approval for use, in patients with metastatic melanoma, non–small cell lung …

The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard… - JCI …, 2016 - pubmed.ncbi.nlm.nih.gov
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …

The head and neck cancer immune landscape and its immunotherapeutic implications.

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI Insight, 2016 - europepmc.org
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …

[引用][C] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI Insight, 2016 - cir.nii.ac.jp
The head and neck cancer immune landscape and its immunotherapeutic implications | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[HTML] jci.org

[HTML][HTML] The head and neck cancer immune landscape and its immunotherapeutic implications

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI …, 2016 - Am Soc Clin Investig
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …

The head and neck cancer immune landscape and its immunotherapeutic implications.

R Mandal, Y Şenbabaoğlu, A Desrichard, JJ Havel… - JCI Insight, 2016 - europepmc.org
Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …